MedTrace Logo

Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma

NCT02801955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2017-06-14

No results posted yet for this study

Summary

For preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma, usage of serum and peritoneal levels of carcinoembryonic antigen (CEA) and CA 19-9 may be helpful. Additionally, the prognosis of the patients with gastric adenocarcinoma treated with gastrectrectomy may be associated with serum and peritoneal levels of tumor markers.

Conditions

  • Gastric Adenocarcinoma

Interventions

PROCEDURE

gastrectomy

radical total/subtotal gastrectomy with D2 lymph node dissection

PROCEDURE

sampling of peritoneal washing aspirate

After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.

Sponsors & Collaborators

  • Bezmialem Vakif University

    lead OTHER

Principal Investigators

  • mustafa hasbahceci, assoc. prof. · bezmialem vakif university faculty of medicine

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-12-31
Completion
2017-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02801955 on ClinicalTrials.gov